Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 11/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3706717 | 1.00 | CSF1R (0.38) | CSF1R | |
| SCHEMBL3649387 | 0.89 | CSF1R (0.36) | CSF1R | |
| SCHEMBL18297750 | 0.86 | CSF1R (0.38) | CSF1R | |
| SCHEMBL3710123 | 0.83 | CSF1R (0.35) | CSF1R | |
| SCHEMBL3715632 | 0.82 | CSF1R (0.38) | CSF1R | |
| SCHEMBL3916494 | 0.80 | CSF1R (0.41) | CSF1R | |
| SCHEMBL4184768 | 0.79 | CSF1R (0.54) | CSF1R | |
| SCHEMBL3165594 | 0.79 | CSF1R (0.40) | CSF1R | |
| SCHEMBL18297742 | 0.79 | CSF1R (0.34) | CSF1R | |
| SCHEMBL16209027 | 0.78 | CSF1R (0.35) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3208269-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-15 | — | — | EP | disclosed |
| EP-3208269-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2215079-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-14 | — | — | EP | disclosed |
| EP-2215079-A1 | INHIBITORS OF C-FMS KINASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009052237-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |